Concepedia

Achim Rittmeyer

AR

Statistics

Publications

61

Citations

14.8K

H-Index

35

Active since

2011

Affiliations

Sungkyunkwan University(Current)

Samsung Medical Center

University of California, Davis

Roche (Switzerland)

UC Davis Comprehensive Cancer Center

Achim Rittmeyer is an author at Sungkyunkwan University specializing in medicine, oncology, and non-small cell lung cancer therapy.

ORCID

Publications per year

2011–2025

61

Publications

61

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text

, , +13

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

, , +12

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology · 2019 · 1.7K citations

, , +12

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz et al. · Nature Medicine · 2018 · 1.2K citations

, , +16

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Fabrice Barlési, Arnaud Scherpereel, Achim Rittmeyer et al. · Journal of Clinical Oncology · 2013 · 327 citations

, , +12

1–5 of 61